Yongkang Xu

5PUBLICATIONS
5CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Oct 06, 2025
Establishment and Validation of a Novel Nutritional-Immune-Inflammatory Score Model for Predicting Survival Prognosis in Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors.

Kan Liu, Yaqin Lv, Shumin Fu

|May 13, 2024
The Value of Chemokine and Chemokine Receptors in Diagnosis, Prognosis, and Immunotherapy of Hepatocellular Carcinoma.

Zhengyi Wu, Liang Sun, Yongkang Xu

|Apr 30, 2024
Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.

Shumin Fu, Yongkang Xu, Ye Mao

|Oct 30, 2023
Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study.

Yongkang Xu, Shumin Fu, Kan Liu

|Oct 10, 2022
Efficacy and Safety of Regorafenib with or without PD-1 Inhibitors as Second-Line Therapy for Advanced Hepatocellular Carcinoma in Real-World Clinical Practice.

Kan Liu, Jianbing Wu, Yongkang Xu

Pageof 1

Frequent Collaborators

1 joint publications

Dan Li

1 joint publications

Shumin Fu

1 joint publications

Jianbing Wu

1 joint publications

Jinlong Yan